Skip to main content

Clarus Therapeutics Holdings, Inc. (CRXT)

NASDAQ: CRXT · IEX Real-Time Price · USD
4.72
0.32 (7.27%)
At close: Dec 7, 2021 4:00 PM
4.60
-0.12 (-2.54%)
After-hours:Dec 7, 2021 7:48 PM EST
Market Cap43.21M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out9.15M
EPS (ttm)-26.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume302,448
Open4.35
Previous Close4.40
Day's Range4.35 - 4.85
52-Week Range3.43 - 9.77
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About CRXT

Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based...

IndustryDrug Manufacturers-General
Founded2003
Employees2
Stock ExchangeNASDAQ
Ticker SymbolCRXT
Full Company Profile

Financial Performance

Financial Statements

News

Clarus Therapeutics Announces $15 Million Private Placement

Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate)

4 days ago - GlobeNewsWire

Clarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)

JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions

1 week ago - GlobeNewsWire

Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results

Third quarter 2021 revenue increased 93% year-over-year to $4.3 million

2 weeks ago - GlobeNewsWire

Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results

NORTHBROOK, Ill., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advan...

2 weeks ago - GlobeNewsWire

Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)

JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical condi...

1 month ago - GlobeNewsWire

Clarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Ann...

JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical condi...

1 month ago - GlobeNewsWire

Clarus Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

NORTHBROOK, Ill., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing andro...

2 months ago - GlobeNewsWire

Clarus Therapeutics, McGill University Ink Licensing Pact For Rare CoQ10-Associated Conditions

Clarus Therapeutics Holdings Inc (NASDAQ: CRXT) and Canada's McGill University have announced licensing agreement whereby Clarus will develop and commercialize McGill's proprietary technology designed t...

Other symbols:CLAR
2 months ago - Benzinga

Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commerciali...

Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to the ...

2 months ago - GlobeNewsWire

Clarus Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

NORTHBROOK, Ill., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by advan...

2 months ago - GlobeNewsWire

Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and M...

Business combination with Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021

2 months ago - GlobeNewsWire

Blue Water Acquisition Corp. Announces Stockholder Approval of Business Combination with Clarus Therapeutics, Inc.

GREENWICH, Conn., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (Nasdaq: BLUW), a special purpose acquisition company (“Blue Water”), today announced that its stockholders have voted to...

3 months ago - GlobeNewsWire

BLUW Stock: 11 Things to Know About Blue Water SPAC Amid Short-Squeeze Rumors

Blue Water Acquisition (BLUW) stock is heading higher on Thursday ahead of the SPAC's upcoming shareholder meeting and recent rumors. The post BLUW Stock: 11 Things to Know About Blue Water SPAC Amid Sh...

3 months ago - InvestorPlace

Blue Water Acquisition Corp. Announces Change of Special Meeting of Shareholders Date to August 27, 2021

NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ: BLUW) (“Blue Water” or the "Company"), a special purpose acquisition company (SPAC) that previously announced a planned ...

3 months ago - GlobeNewsWire

Blue Water Acquisition Corp. Announces Date for Special Meeting of Stockholders to Vote on Transaction With Clarus Th...

GREENWICH, Conn., July 30, 2021 /PRNewswire/ --  Blue Water Acquisition Corp. (Nasdaq: BLUW) ("Blue Water"), a special purpose acquisition company ("SPAC") led by Joseph Hernandez, today announced that ...

4 months ago - PRNewsWire

Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Infla...

NORTHBROOK, Ill. and NORTH ADELAIDE, South Australia, May 25, 2021 /PRNewswire/ -- Clarus Therapeutics Inc. ("Clarus"), a pharmaceutical company dedicated to providing solutions to unmet medical needs b...

6 months ago - PRNewsWire

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Blue Water Acquisition Corp. - BLUW

NEW YORK, May 4, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action S...

7 months ago - PRNewsWire